Novartis ADR earnings beat by $0.18, revenue fell short of estimates

Novartis (NYSE: NVS) reported Q3 EPS of $2.46, beating estimates by $0.18, but revenue of $14.52B missed expectations. Shares closed at $153.81, down 2.92% over 3 months but up 24.61% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
Published Oct 27, 2026, 6:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The earnings surprise provides a fresh catalyst for short-term trading, with potential upside for the stock.

02

Market read

Earnings beat is a primary corporate event that can move the stock and influence sector sentiment.

03

What to watch

Guidance outlook and pipeline updates were not disclosed, which could temper the reaction.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Novartis ADR (NYSE: NVS) released its third-quarter earnings, showing an EPS beat and slight revenue shortfall.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis ADR reported Q3 EPS of $2.46, beating estimates by $0.18 and revenue of $14.52B versus $14.6B consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat exceeds expectations and is the first report of the numbers, providing fresh material for traders.

Market effects

May lift broader pharma sector as peers are compared to the beat.

European markets could see modest gains on the news.

Limited to healthcare investors; no broad market shift expected.

Counterpoint

The revenue miss could signal underlying demand weakness, limiting upside.

Key entities

  • Novartis ADR

    Swiss pharmaceutical giant listed on NYSE as NVS.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.